Amylin Pharmaceuticals Company Profile

Aggregated data from the web about Amylin Pharmaceuticals

Company Name	Amylin Pharmaceuticals
Website	https://en.wikipedia.org
Snippet	Amylin, or islet amyloid polypeptide (IAPP), is a 37-residue peptide hormone. It is co-secreted with insulin from the pancreatic β-cells in the ratio of approximately 100:1 (insulin:amylin). Amylin plays a role in glycemic regulation by slowing gastric emptying and promoting satiety, thereby preventing post-prandial spikes in blood glucose levels.. IAPP is processed from an 89-residue …
Fate	Acquired by Bristol-Myers Squibb and AstraZeneca
Type	Subsidiary
Defunct	2012; 10 years ago (2012)
Founded	1987
Revenue	US$651 million (2011)[2]
Industry	Biotechnology
Products	Symlin (pramlintide)Byetta (exenatide)Bydureon (exenatide long-acting release)
Traded as	NASDAQ: AMLN
Key people	Daniel M. Bradbury[1]
Net income	US$−543 million (2011)[2]
Headquarters	San Diego, California, United States
Subsidiaries	Amylin Ohio LLC
Total assets	US$1.87 billion (2011)[2]
Total equity	US$−139 million (2011)[2]
Number of employees	1,300 (2011)[2]

Amylin Pharmaceuticals is part of the United States company list

Amylin Pharmaceuticals is part of the Biotechnology company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.